Tirzepatide: the dual GIP/GLP-1 agonist

Tirzepatide marked a turning point in metabolic peptide research: a single synthetic molecule designed to engage two incretin receptors at once. Understanding why that matters is the key to understanding the whole modern GLP-1 research field.

Two pathways, one molecule

Incretins are hormones the gut releases in response to food. Two of them — GLP-1 and GIP — are central to how the body regulates blood glucose and appetite signalling in laboratory models. Earlier research peptides engaged GLP-1 alone. Tirzepatide is studied as a dual agonist, activating both GLP-1 and GIP receptors simultaneously.

Why the dual approach draws attention

In the published research literature, combining GLP-1 and GIP activity has been associated with stronger effects on metabolic markers in study models than single-pathway compounds. This is what positioned tirzepatide between semaglutide (single pathway) and retatrutide (triple pathway) in the research lineage. Our article on GLP-1 analogues compares all three side by side.

Form and handling

Like other research peptides, tirzepatide is supplied as a lyophilised powder for stability and reconstituted with bacteriostatic water before use. Vela supplies it in multiple vial sizes; our reconstitution and storage guide and the on-site reconstitution simulator help you plan the right dilution.

Purity and documentation

Reproducible research depends on knowing exactly what a vial contains. Every Vela batch is supplied with a certificate of analysis — confirming identity and purity — issued within six months of sale.